Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Jones

Showing results (21-30 of 264) with videos related to

Pageof 27
Sort By:
Experimental Hematology|July 30, 2017
Retinoic acid, CYP26, and drug resistance in the stem cell nicheSalvador Alonso, Richard J Jones, Gabriel Ghiaur
Blood Advances|March 24, 2026
Donor type outcomes in setting of PTCy: more apparent than real?Joseph A Pidala, Ravi Varadhan, Richard J Jones
Current Opinion in Hematology|September 10, 2010
High-dose cyclophosphamide for graft-versus-host disease preventionLeo Luznik, Richard J Jones, Ephraim J Fuchs
Nature Reviews. Clinical Oncology|September 30, 2009
Cyclophosphamide and cancer: golden anniversaryAshkan Emadi, Richard J Jones, Robert A Brodsky
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 1, 2006
Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamideJavier Bolaños-Meade, Eric Hartley, Richard J Jones
Arthritis and Rheumatism|January 16, 2003
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosusMichelle Petri, Richard J Jones, Robert A Brodsky
Current Opinion in Oncology|April 13, 2004
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplantGreg R Angstreich, B Douglas Smith, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 29, 2018
Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit EngraftmentAmy E DeZern, Richard J Jones, Robert A Brodsky
Annals of Neurology|January 2, 2003
Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamideDaniel B Drachman, Richard J Jones, Robert A Brodsky
Journal of the National Cancer Institute|April 22, 2004
Cancer stem cells: are we missing the target?Richard J Jones, William H Matsui, B Douglas Smith
Pageof 27

Showing results (21-30 of 264) with videos related to

Sort By:
Pageof 27
Experimental Hematology|July 30, 2017
Retinoic acid, CYP26, and drug resistance in the stem cell nicheSalvador Alonso, Richard J Jones, Gabriel Ghiaur
Blood Advances|March 24, 2026
Donor type outcomes in setting of PTCy: more apparent than real?Joseph A Pidala, Ravi Varadhan, Richard J Jones
Current Opinion in Hematology|September 10, 2010
High-dose cyclophosphamide for graft-versus-host disease preventionLeo Luznik, Richard J Jones, Ephraim J Fuchs
Nature Reviews. Clinical Oncology|September 30, 2009
Cyclophosphamide and cancer: golden anniversaryAshkan Emadi, Richard J Jones, Robert A Brodsky
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 1, 2006
Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamideJavier Bolaños-Meade, Eric Hartley, Richard J Jones
Arthritis and Rheumatism|January 16, 2003
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosusMichelle Petri, Richard J Jones, Robert A Brodsky
Current Opinion in Oncology|April 13, 2004
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplantGreg R Angstreich, B Douglas Smith, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 29, 2018
Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit EngraftmentAmy E DeZern, Richard J Jones, Robert A Brodsky
Annals of Neurology|January 2, 2003
Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamideDaniel B Drachman, Richard J Jones, Robert A Brodsky
Journal of the National Cancer Institute|April 22, 2004
Cancer stem cells: are we missing the target?Richard J Jones, William H Matsui, B Douglas Smith
Pageof 27